Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Advances in Ovarian tumor Therapy Made at LIMR

Abstract:
Cancer Research paper shows Nanoparticle Delivery System Slowed Ovarian Tumor Growth

Advances in Ovarian tumor Therapy Made at LIMR

Wynnewood, PA | Posted on September 4th, 2009

Ovarian cancer is the fifth leading cause of cancer-related death in women and remains the leading cause of cancer death from gynecologic cancers. Currently, there is no effective therapy for patients with advanced ovarian cancer. Dr. Janet Sawicki, Professor at the Lankenau Institute for Medical Research (LIMR), along with its collaborating institution, the Massachusetts Institute of Technology (MIT), published a paper in Cancer Research whose findings suggest a potential new therapy to treat advanced stage ovarian cancer. Dr. Sawicki and her colleagues conducted preclinical tests using three different animal models to evaluate the therapeutic efficacy of using nanoparticles to deliver a diphtheria toxin suicide gene. DNA sequences, called promoters, were used to target production of the toxin protein to tumor cells. Nanoparticles were injected directly into tumors or injected into the peritoneal cavity where most of the tumors are located.

Treatment with the nanotherapy reduced tumor mass and prolonged lifespan as compared to the
control group. It also suppressed tumor growth better than two commonly used chemotherapeutic drugs, cisplatin and paclitaxel. The researchers observed very little non-specific toxicity in normal, healthy tissues.

"Unlike chemotherapy, which can destroy both cancer and healthy cells and lead to many adverse effects, this new therapy specifically targets cancer cells and leaves the healthy cells alone," stated Dr. Sawicki. "Our hope is to begin doing clinical trials in patients in the next 18 to 24 months and then potentially tailor this therapy to treat different solid tumor types including pancreatic, prostate, and cervical cancers."

A resident of Newtown Square, PA, Dr. Sawicki joined the LIMR staff in 1990 after serving as an Assistant Professor at the Wistar Institute. She received her Ph.D. in Genetics from Cornell University and her B.A. in Biology from the University of Delaware. Dr. Sawicki also completed postdoctoral work at Yale University and the University of California, San Francisco. She currently serves as an Associate Professor in the Kimmel Cancer Center at Thomas Jefferson University. Her ovarian cancer research is funded by the NIH, the Department of Defense, the Sandy Rollman Foundation, WAWA, the Teal Ribbon Ovarian Cancer Foundation, and the Kaleidoscope of Hope Foundation.

####

About Lankenau Institute for Medical Research
Founded in 1927, the Lankenau Institute for Medical Research (LIMR) is an independent, nonprofit biomedical research center located in suburban Philadelphia on the campus of the Lankenau Hospital. As part of the Main Line Health System, LIMR is one of the few freestanding, hospital-associated medical research centers in the nation. The faculty and staff at the Institute are dedicated to advancing an understanding of the causes of cancer and heart disease. They use this information to help improve diagnosis and treatment of these diseases as well as find ways to prevent them. They are also committed to extending the boundaries of human health and well-being through technology transfer and education directed at the scientific, clinical, business and lay public communities.

About Cancer Research

Cancer Research is published twice a month, one volume/year, by the American Association for Cancer Research, Inc. It publishes significant, original studies in all areas of basic, clinical, translational, epidemiological, and prevention research devoted to the study of cancer and cancer-related biomedical sciences. Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit are accepted for publication.

About David H. Koch Institute for Integrative Cancer Research at MIT

Launched by MIT in 2008, the David H. Koch Institute for Integrative Cancer Research (KI) both transforms and transcends the Center for Cancer Research (CCR). CCR was founded in 1974 by Nobel Laureate and MIT Professor Salvador Luria, CCR has made enormous contributions to the field of cancer research. The Koch is one of only seven National Cancer Institute-designated basic research centers in the US and is comprised of faculty that have earned the most prestigious national and international science honors including the Nobel Prize and the National Medal of Science. For more information visit: web.mit.edu/ki/index.html.

For more information, please click here

Contacts:
Tava Shanchuk
(610) 645-3429

Copyright © Lankenau Institute for Medical Research

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Ultracold atom waves may shed light on rogue ocean killers: Rice quantum experiments probe underlying physics of rogue ocean waves April 27th, 2017

Looking for the quantum frontier: Beyond classical computing without fault-tolerance? April 27th, 2017

Metal nanoparticles induced visible-light photocatalysis: Mechanisms, applications, ways of promoting catalytic activity and outlook April 27th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

Possible Futures

Looking for the quantum frontier: Beyond classical computing without fault-tolerance? April 27th, 2017

Video captures bubble-blowing battery in action: Researchers propose how bubbles form, could lead to smaller lithium-air batteries April 26th, 2017

California Research Alliance by BASF establishes more than 25 research projects in three years April 26th, 2017

Geoffrey Beach: Drawn to explore magnetism: Materials researcher is working on the magnetic memory of the future April 25th, 2017

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

New Product Nanoparticle preparation from Intertronics with new Thinky NP-100 Nano Pulveriser April 26th, 2017

Nanoparticle vaccine shows potential as immunotherapy to fight multiple cancer types April 24th, 2017

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM) April 20th, 2017

Announcements

Ultracold atom waves may shed light on rogue ocean killers: Rice quantum experiments probe underlying physics of rogue ocean waves April 27th, 2017

Looking for the quantum frontier: Beyond classical computing without fault-tolerance? April 27th, 2017

Metal nanoparticles induced visible-light photocatalysis: Mechanisms, applications, ways of promoting catalytic activity and outlook April 27th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

Nanobiotechnology

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

Nanoparticle vaccine shows potential as immunotherapy to fight multiple cancer types April 24th, 2017

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM) April 20th, 2017

Nano-SPEARs gently measure electrical signals in small animals: Rice University's tiny needles simplify data gathering to probe diseases, test drugs April 17th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project